Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis

Open access
Rahaghi, Franck F., Baughman, Robert P., Saketkoo, Lesley Ann, Sweiss, Nadera J., Barney, Joseph B., Birring, Surinder S., Costabel, Ulrich, Crouser, Elliott D., Drent, Marjolein, Gerke, Alicia K., Grutters, Jan C., Hamzeh, Nabeel Y., Huizar, Isham, Ennis James, W., Kalra, Sanjay, Kullberg, Susanna, Li, Huiping, Lower, Elyse E., Maier, Lisa A., Mirsaeidi, Mehdi, Müller-Quernheim, Joachim, Carmona Porquera, Eva M., Samavati, Lobelia, Valeyre, Dominique, Scholand, Mary Beth·2020·European Respiratory Review

Abstract

Pulmonary sarcoidosis presents substantial management challenges, with limited evidence on effective therapies and phenotypes. In the absence of definitive evidence, expert consensus can supply clinically useful guidance in medicine. An international panel of 26 experts participated in a Delphi process to identify consensus on pharmacological management in sarcoidosis with the development of preliminary recommendations. The modified Delphi process used three rounds. The first round focused on qualitative data collection with open-ended questions to ensure comprehensive inclusion of expert concepts. Rounds 2 and 3 applied quantitative assessments using an 11-point Likert scale to identify consensus. Key consensus points included glucocorticoids as initial therapy for most patients, with non-biologics (immunomodulators), usually methotrexate, considered in severe or extrapulmonary disease requiring prolonged treatment, or as a steroid-sparing intervention in cases with high risk of steroid toxicity. Biologic therapies might be considered as additive therapy if non-biologics are insufficiently effective or are not tolerated with initial biologic therapy, usually with a tumour necrosis factor-α inhibitor, typically infliximab. The Delphi methodology provided a platform to gain potentially valuable insight and interim guidance while awaiting evidenced-based contributions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/16000617.0146-2019

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 167

Metadata

Authors
Rahaghi, F. F., Baughman, R. P., Saketkoo, L. A., Sweiss, N. J., Barney, J. B., Birring, S. S., Costabel, U., Crouser, E. D., Drent, M., Gerke, A. K., Grutters, J. C., Hamzeh, N. Y., Huizar, I., Ennis James, W., Kalra, S., Kullberg, S., Li, H., Lower, E. E., Maier, L. A., Mirsaeidi, M., Müller-Quernheim, J., Carmona Porquera, E. M., Samavati, L., Valeyre, D., & Scholand, M. B.
Venue
European Respiratory Review
Published
2020-03-20
Volume
29
Issue
155
Pages
190146
ISSN
  • 0905-9180 (ISSN-L)
  • 1600-0617
OpenAlex
W3012439880
Cited by
167
References
2
FWCI
12.57
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. https://app.cochat.ai/papers/10.1183/16000617.0146-2019
The paper
Rahaghi, F. F., Baughman, R. P., Saketkoo, L. A., Sweiss, N. J., Barney, J. B., Birring, S. S., Costabel, U., Crouser, E. D., Drent, M., Gerke, A. K., Grutters, J. C., Hamzeh, N. Y., Huizar, I., Ennis James, W., Kalra, S., Kullberg, S., Li, H., Lower, E. E., Maier, L. A., . . . Scholand, M. B. (2020). Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. European Respiratory Review. https://doi.org/10.1183/16000617.0146-2019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.